Suggested remit: To appraise the clinical and cost effectiveness of momelotinib within its marketing authorisation for treating disease-related splenomegaly or symptoms from myelofibrosis.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6141

Provisional Schedule

Expected publication 20 March 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors GSK (momelotinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Leukaemia Care
  MPN Voice
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Novartis (ruxolitinib) (confidentiality agreement signed, participating)
  Masters Pharmaceuticals (hydroxycarbamide) (confidentiality agreement not signed, not participating)
  medac GmbH (hydroxycarbamide) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
15 February 2024 - 29 February 2024 Final draft guidance
09 January 2024 Committee meeting
06 June 2023 Invitation to participate
24 January 2023 - 21 February 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 January 2023 In progress. Scoping commenced
15 June 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual